Refine
Year of publication
Document Type
- Preprint (62)
- Article (51)
- Part of Periodical (3)
- Working Paper (1)
Has Fulltext
- yes (117)
Is part of the Bibliography
- no (117)
Keywords
- Bibliographie (3)
- Film (3)
- Hadron-Hadron Scattering (3)
- Heavy Ions (3)
- Charm physics (2)
- ALICE experiment (1)
- ATM (1)
- Anti-seizure medication (1)
- BFIS (1)
- Beauty production (1)
- Cancer (1)
- Chemotherapy (1)
- Cleanliness level (1)
- Colon capsule endoscopy (1)
- Complementation rate (1)
- DNA-PK (1)
- Epilepsy (1)
- Everolimus (1)
- Formalismus (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heavy-ion collision (1)
- IR (1)
- Incomplete colonoscopy (1)
- Jets (1)
- LHC (1)
- Low volume prep (1)
- Lung Cancer (1)
- MYC (1)
- Moviprep (1)
- NOTCH (1)
- NSCLC (1)
- Neoformalismus <Film> (1)
- Non-small cell lung cancer (1)
- PI3K (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- PTEN (1)
- Phospho-soda (1)
- PillCamColon2 (1)
- Polyps (1)
- Prognosis (1)
- QCD (1)
- Quark gluon plasma (1)
- ROS1 (1)
- Radiotherapy (1)
- Relativistic heavy ion physics (1)
- Rhabdomyoma (1)
- Seizure (1)
- Single electrons (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- USP28 (1)
- Wisconsin Projekt (1)
- core facility administration (1)
- diffuse large B cell lymphoma (1)
- familial infantile epilepsy (1)
- gene expression profiling (1)
- hemiplegic migraine (1)
- host response (1)
- instrument performance tests (1)
- mTOR inhibitor (1)
- microscopy room requirements (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- phenotypic spectrum (1)
- pp collisions (1)
- squamous cell carcinoma (1)
- user and staff training (1)
- user/staff/instrument ratio (1)
- ΔNp63 (1)
Institute
The transcription factor ∆Np63 is a master regulator of epithelial cell identity and essential for the survival of squamous cell carcinoma (SCC) of lung, head and neck, oesophagus, cervix and skin. Here, we report that the deubiquitylase USP28 stabilizes ∆Np63 and maintains elevated ∆NP63 levels in SCC by counteracting its proteasome‐mediated degradation. Impaired USP28 activity, either genetically or pharmacologically, abrogates the transcriptional identity and suppresses growth and survival of human SCC cells. CRISPR/Cas9‐engineered in vivo mouse models establish that endogenous USP28 is strictly required for both induction and maintenance of lung SCC. Our data strongly suggest that targeting ∆Np63 abundance via inhibition of USP28 is a promising strategy for the treatment of SCC tumours.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.
Die Lichtabsorptionseigenschaften einer Reihe von Lösungen der Komplexionen des dreiwertigen Vanadins vom Typus [V A6]3+, wo A H2O, CH3OH, C2H5OH sowie iso-C4H9OH ist, wurden gemessen. Ferner wurden die Absorptionsspektren von kristallisiertem Ammonium-sowie Caesiumvanadin(III)-alaun aufgenommen.
Intensitätsverhältnisse und spektrale Lage der in allen Spektren auftretenden langwelligen Banden stehen in guter Übereinstimmung mit den Aussagen der Theorie für den Fall eines Zentralions mit zwei d-Elektronen bei Oh-Symmetrie des Komplexfeldes.
Es wird gezeigt, daß man die langwelligen Absorptionsspektren der magnetisch normalen oktaedrischen Komplexionen mit den Übergangsmetallionen Ti3+, V3+, Cr3+, Mn3+ und Fe3+ verstehen kann, wenn man annimmt, daß die schwachen langwelligen Banden durch Übergänge zwischen den Aufspaltungsprodukten der jeweiligen Grundterme entstehen, wobei die Auf-spaltungen durch das elektrostatische Feld der Liganden zustande kommen.
Aim: To evaluate the ability of PillCamColon2 to visualize colonic segments missed by incomplete optical colonoscopy (OC) and to assess the diagnostic yield.
Methods: This prospective multicentre study included 81 patients from nine centres who underwent second-generation colon capsule endoscopy (CCE) following incomplete OC performed by an experienced gastroenterologist (> 1000 colonoscopies). Patients with stenosis were excluded. According to patient preferences, CCE was performed the following day (protocol A) after staying on clear liquids and 0.75 L Moviprep in the morning or within 30 d after new split-dose Moviprep (protocol B). Boosts consisted of 0.75 L and 0.25 L Moviprep, and phospho-soda was given as a rescue if the capsule was not excreted after seven hours.
Results: Seventy-four patients were analysed (51% of them in group A; 49% in group B). Bowel cleansing was adequate in 67% of cases, and CCE could visualize colonic segments missed by incomplete colonoscopy in 90% of patients under protocol A and 97% of patients under protocol B (P = 0.35, n.s.). Significant polyps including adenocarcinoma were detected in 24% of cases. Detection rates for all polyps and significant polyps per patient were similar in both protocols. Polyps were found predominantly in the right colon (86%) in segments that were not reached by OC. Extracolonic findings - such as reflux esophagitis, suspected Barrett esophagus, upper GI-bleeding, gastric polyps, gastric erosions and angiectasia - were detected in eight patients. PillCamColon2 capsule was retained in the ileum of one patient (1.4%) without symptoms and removed during an uneventful resection for unknown Crohn’s disease that was diagnosed as the cause of anemia, which was the indication for colonoscopy. CCE was well tolerated. One patient suffered from self-limiting vomiting after consuming the phospho-soda.
Conclusion: Second-generation CCE using a low-volume preparation is useful after incomplete OC, and it allows for the detection of additional relevant findings, but cleansing efficiency could be improved.
Background: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1- positive patients.
Patients and methods: 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients.
Results: 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations.
Conclusion: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.